N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=171 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic Arthritis
Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score
N/A N=178 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis · Psoriatic Arthritis · Periodontal Disease
Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
N/A N=52 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 3 N=851 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 — 50.7; 60.9; 65.0 percentage of participants — p=0.005
N/A N=96 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months — -1.4 units on a scale
Phase 2 N=165 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Arthritis, Psoriatic
Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants
Phase 3 N=77 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
Rheumatoid Arthritis · Psoriatic Arthritis
Primary: Percentage of Successful Self-injections to Total Non-missed Injections — 97.8 percentage of successful injections
Phase 4 N=1,013 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
N/A N=353 Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Phase 4 N=27 IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
Rheumatoid Arthritis
Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…
Phase 4 N=234 An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants
Phase 4 N=63 Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3
N/A N=145 The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change in Heart Rate Variability (HRV) Measure — 13.38; -13.48 ms
N/A N=79 Living Well With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 4 N=217 Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
Rheumatoid Arthritis · Plaque Psoriasis
Primary: Percentage of Participants With a Preference for Autoinjector A Versus Autoinjector B — 41.7; 43.5; 36.8 percentage of participants
Phase 4 N=752 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis — 176; 119 participants
N/A N=13,182 Comorbidities and Outcomes in Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years
N/A N=155 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Participant Assessment of Present Pain Intensity Recorded on a Visual Analogue Scale (VAS) at Baseline and Months 3, 6, 9, and 12 — 58.32; 34.28; 27.14; 21.71 units on a…
Phase 3 N=25 Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01
N/A N=24 Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk
Rheumatoid Arthritis
Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05
N/A N=161 Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI — 1.2; 0.9; 1.1; 0.9 Units on a scale
Phase 4 N=210 Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055
N/A N=200 Depression and Anxiety in Rheumatoid Arthritis
Rheumatoid Arthritis · Depression · Anxiety
Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants
N/A N=101 Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:
Rheumatoid Arthritis · Cardiovascular Diseases · Hyperlipidemias
Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…
N/A N=48 T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Measurement of Effector T Helper Type 17 Cells in Peripheral Blood — 466.4; 432; 450; 759.8 spSFC/10^6 — p=0.003
N/A N=156 Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment
Rheumatoid Arthritis
Primary: Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression — 6.9; 24.3; 0.0; 0.3 scores on a scale